OVID
Ovid Therapeutics Accelerates Pipeline Progress with Regulatory Clearance and Significant Funding
In a major milestone, Ovid Therapeutics announced regulatory clearance for the first-ever oral KCC2 direct activator, OV4071, during its recent Q4 2025 conference call. This achievement marks significant progress in the company's pipeline, with all programs advancing on track to patient proof-of-concept studies. According to Meg Alexander, President